Search

Your search keyword '"Zhu N"' showing total 23 results
Start Over Author "Zhu N" Journal leukemia research
23 results on '"Zhu N"'

1. Topic: AS09-Quality of life-Disease experiences: LONGITUDINAL TRAJECTORY OF QUALITY OF LIFE IN MDS AND IMPACT OF PATIENT-RELATED FACTORS

Author

Buckstein, R., primary, Chodirker, L., additional, Mozessohn, L., additional, Geddes, M., additional, Zhu, N., additional, Trottier, A., additional, Khalaf, D., additional, Leber, B., additional, St-Hilaire, E., additional, Finn, N., additional, Sabloff, M., additional, Christou, G., additional, Leitch, H., additional, Shamy, A., additional, Yee, K., additional, Storring, J., additional, Nevill, T., additional, Elemary, M., additional, Delage, R., additional, Houston, B., additional, Parmentier, A., additional, Siddiqui, M., additional, Mamedov, A., additional, Zhang, L., additional, and Abel, G., additional

Published
2023
Full Text
View/download PDF

2. Topic: AS08-Treatment/AS08f-Clinical trials – Phase II-III: RANDOMIZED PHASE 2 STUDY TO ASSESS SAFETY AND EFFICACY OF LOW-DOSE (LD) ORAL DECITABINE/CEDAZURIDINE (ASTX727) IN LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS) PATIENTS: INTERIM SAFETY ANALYSIS

Author

Garcia-Manero, G., primary, Bachiashvili, K., additional, Griffiths, E., additional, Traer, E., additional, Saini, L., additional, Amin, H., additional, Zeidan, A., additional, Mohan, S., additional, Lübbert, M., additional, Maness, L., additional, Foran, J., additional, Selleslag, D., additional, Xicoy, B., additional, Pollyea, D., additional, Sallman, D., additional, Al-Kali, A., additional, Berdeja, J., additional, Al-Ali, H., additional, Zhu, N., additional, Lopez, P. Font, additional, Sanz, G., additional, Santini, V., additional, Yimer, H., additional, Cripe, L., additional, Priego, V., additional, Odenike, O., additional, Heyrman, B., additional, Valcárcel, D., additional, Vachhani, P., additional, Sano, Y., additional, Mirakhur, B., additional, Oganesian, A., additional, Keer, H., additional, and Yacoub, A., additional

Published
2023
Full Text
View/download PDF

3. Topic: AS02-Epidemiology: EVALUATION OF INFECTIOUS COMPLICATIONS IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES: A PROSPECTIVE COHORT STUDY FROM THE CANADIAN MDS REGISTRY

Author

Mathur, S., primary, Christou, G., additional, Delage, R., additional, Elemary, M., additional, Finn, N., additional, Geddes, M., additional, Houston, D., additional, Keating, M.-M., additional, Khalaf, D., additional, Leber, B., additional, Leitch, H., additional, Lother, S., additional, Mozessohn, L., additional, Nevill, T., additional, Parmentier, A., additional, Paulson, K., additional, Rimmer, E., additional, Sabloff, M., additional, Shamy, A., additional, St-Hilaire, E., additional, Storring, J., additional, Yee, K., additional, Zhang, L., additional, Zhu, N., additional, Hay, A., additional, Zarychanski, R., additional, Buckstein, R., additional, and Houston, B., additional

Published
2023
Full Text
View/download PDF

4. Topic: AS08-Treatment/AS08f-Clinical trials – Phase II-III: EFFICACY AND SAFETY OF ORAL DECITABINE/CEDAZURIDINE (ASTX727) IN THE CMML SUBPOPULATION FROM PHASE 2 AND ASCERTAIN PHASE 3 STUDIES

Author

Savona, M., primary, Mccloskey, J., additional, Griffiths, E., additional, Yee, K., additional, Zeidan, A., additional, Al-Kali, A., additional, Deeg, H.J., additional, Patel, P., additional, Sabloff, M., additional, Keating, M.-M., additional, Zhu, N., additional, Gabrail, N., additional, Fazal, S., additional, Maly, J., additional, Odenike, O., additional, Kantarjian, H., additional, Dezern, A., additional, O’Connell, C., additional, Roboz, G., additional, Busque, L., additional, Buckstein, R., additional, Amin, H., additional, Randhawa, J., additional, Leber, B., additional, Dao, K.-H., additional, Sano, Y., additional, Mirakhur, B., additional, Keer, H., additional, and Garcia-Manero, G., additional

Published
2023
Full Text
View/download PDF

5. P143 - Topic: AS09-Quality of life-Disease experiences: LONGITUDINAL TRAJECTORY OF QUALITY OF LIFE IN MDS AND IMPACT OF PATIENT-RELATED FACTORS

Author

Buckstein, R., Chodirker, L., Mozessohn, L., Geddes, M., Zhu, N., Trottier, A., Khalaf, D., Leber, B., St-Hilaire, E., Finn, N., Sabloff, M., Christou, G., Leitch, H., Shamy, A., Yee, K., Storring, J., Nevill, T., Elemary, M., Delage, R., Houston, B., Parmentier, A., Siddiqui, M., Mamedov, A., Zhang, L., and Abel, G.

Published
2023
Full Text
View/download PDF

6. P135 - Topic: AS08-Treatment/AS08f-Clinical trials – Phase II-III: RANDOMIZED PHASE 2 STUDY TO ASSESS SAFETY AND EFFICACY OF LOW-DOSE (LD) ORAL DECITABINE/CEDAZURIDINE (ASTX727) IN LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS) PATIENTS: INTERIM SAFETY ANALYSIS

Author

Garcia-Manero, G., Bachiashvili, K., Griffiths, E., Traer, E., Saini, L., Amin, H., Zeidan, A., Mohan, S., Lübbert, M., Maness, L., Foran, J., Selleslag, D., Xicoy, B., Pollyea, D., Sallman, D., Al-Kali, A., Berdeja, J., Al-Ali, H., Zhu, N., Lopez, P. Font, Sanz, G., Santini, V., Yimer, H., Cripe, L., Priego, V., Odenike, O., Heyrman, B., Valcárcel, D., Vachhani, P., Sano, Y., Mirakhur, B., Oganesian, A., Keer, H., and Yacoub, A.

Published
2023
Full Text
View/download PDF

7. P136 - Topic: AS08-Treatment/AS08f-Clinical trials – Phase II-III: EFFICACY AND SAFETY OF ORAL DECITABINE/CEDAZURIDINE (ASTX727) IN THE CMML SUBPOPULATION FROM PHASE 2 AND ASCERTAIN PHASE 3 STUDIES

Author

Savona, M., Mccloskey, J., Griffiths, E., Yee, K., Zeidan, A., Al-Kali, A., Deeg, H.J., Patel, P., Sabloff, M., Keating, M.-M., Zhu, N., Gabrail, N., Fazal, S., Maly, J., Odenike, O., Kantarjian, H., Dezern, A., O’Connell, C., Roboz, G., Busque, L., Buckstein, R., Amin, H., Randhawa, J., Leber, B., Dao, K.-H., Sano, Y., Mirakhur, B., Keer, H., and Garcia-Manero, G.

Published
2023
Full Text
View/download PDF

8. P025 - Topic: AS02-Epidemiology: EVALUATION OF INFECTIOUS COMPLICATIONS IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES: A PROSPECTIVE COHORT STUDY FROM THE CANADIAN MDS REGISTRY

Author

Mathur, S., Christou, G., Delage, R., Elemary, M., Finn, N., Geddes, M., Houston, D., Keating, M.-M., Khalaf, D., Leber, B., Leitch, H., Lother, S., Mozessohn, L., Nevill, T., Parmentier, A., Paulson, K., Rimmer, E., Sabloff, M., Shamy, A., St-Hilaire, E., Storring, J., Yee, K., Zhang, L., Zhu, N., Hay, A., Zarychanski, R., Buckstein, R., and Houston, B.

Published
2023
Full Text
View/download PDF

9. P48 - Topic: AS08-Treatment/AS08a-Current treatment options - Hypomethylating agents: PROLONGED SURVIVAL OBSERVED IN 133 MDS PATIENTS TREATED WITH ORAL DECITABINE/CEDAZURIDINE

Author

Savona, M., Mccloskey, J., Griffiths, E., Yee, K., Al-Kali, A., Zeidan, A.M., Deeg, H.J., Patel, P., Sabloff, M., Keating, M.-M., Dao, K.-H., Zhu, N., Gabrail, N., Fazal, S., Maly, J., Odenike, O., Kantarjian, H., Dezern, A., O’Connell, C., Roboz, G., Busque, L., Wells, R., Amin, H., Randhawa, J., Leber, B., Hao, Y., Keer, H., Azab, M., and Manero, G. Garcia

Published
2021
Full Text
View/download PDF

11. P09 - Topic: AS02-Epidemiology: THE IMPACT OF GAINING OR LOSING TRANSFUSION INDEPENDENCE ON QUALITY OF LIFE IN MYELODYSPLASTIC SYNDROMES

Author

Brailovski, E., Mozessohn, L., Abel, G., Geddes, M., Zhu, N., Keating, M.-M., Sabloff, M., Christou, G., Leber, B., Khalaf, D., Leitch, H., Hilaire, E. St., Finn, N., Shamy, A., Yee, K., Storring, J., Nevill, T., Delage, R., Elemary, M., Banerji, V., Houston, B., Chodirker, L., Parmentier, A., Siddiqui, M., Mamedov, A., Zhang, L., and Buckstein, R.

Published
2021
Full Text
View/download PDF

12. Topic: AS08-Treatment/AS08j-Supportive care - Iron overload

Author

Leitch, H., primary, Ezzat, H., additional, Merkeley, H., additional, Buckstein, R., additional, Zhu, N., additional, Nevill, T., additional, Olney, H., additional, Yee, K., additional, Leber, B., additional, Keating, M.-M., additional, Hilaire, E. St., additional, Kumar, R., additional, Delage, R., additional, Geddes, M., additional, Storring, J., additional, Shamy, A., additional, Elemary, M., additional, and Wells, R., additional

Published
2021
Full Text
View/download PDF

13. Topic: AS02-Epidemiology

Author

Brailovski, E., primary, Mozessohn, L., additional, Abel, G., additional, Geddes, M., additional, Zhu, N., additional, Keating, M.-M., additional, Sabloff, M., additional, Christou, G., additional, Leber, B., additional, Khalaf, D., additional, Leitch, H., additional, Hilaire, E. St., additional, Finn, N., additional, Shamy, A., additional, Yee, K., additional, Storring, J., additional, Nevill, T., additional, Delage, R., additional, Elemary, M., additional, Banerji, V., additional, Houston, B., additional, Chodirker, L., additional, Parmentier, A., additional, Siddiqui, M., additional, Mamedov, A., additional, Zhang, L., additional, and Buckstein, R., additional

Published
2021
Full Text
View/download PDF

14. Topic: AS08-Treatment/AS08a-Current treatment options - Hypomethylating agents

Author

Savona, M., primary, Mccloskey, J., additional, Griffiths, E., additional, Yee, K., additional, Al-Kali, A., additional, Zeidan, A.M., additional, Deeg, H.J., additional, Patel, P., additional, Sabloff, M., additional, Keating, M.-M., additional, Dao, K.-H., additional, Zhu, N., additional, Gabrail, N., additional, Fazal, S., additional, Maly, J., additional, Odenike, O., additional, Kantarjian, H., additional, Dezern, A., additional, O’Connell, C., additional, Roboz, G., additional, Busque, L., additional, Wells, R., additional, Amin, H., additional, Randhawa, J., additional, Leber, B., additional, Hao, Y., additional, Keer, H., additional, Azab, M., additional, and Manero, G. Garcia, additional

Published
2021
Full Text
View/download PDF

15. MDS-Can-It: A New Validated International ESA-Response Score that Further Refines the Predictive Power of the Nordic Scoring System

Author

Buckstein, R., primary, Balleari, E., additional, Wells, R.A., additional, Santini, V., additional, Salvetti, C., additional, Allione, B., additional, Danise, P., additional, Finelli, C., additional, Clavio, M., additional, Zhu, N., additional, Michelle, G., additional, Sabloff, M., additional, Leitch, H., additional, Leber, B., additional, Luca, M., additional, Latagliata, R., additional, Antonietta, M., additional, Villivà, N., additional, Piccioni, A.L., additional, and Buccisano, F., additional

Published
2017
Full Text
View/download PDF

16. Improved Survival from Transfusion Dependence in Lower-Risk MDS Receiving Iron Chelation, Adjusting for MDS and Patient Characteristics: An MDS-Can Analysis

Author

Leitch, H.A., primary, Wells, R.A., additional, Chodirker, L., additional, Zhu, N., additional, Nevill, T.J., additional, Yee, K.W.L., additional, Leber, B., additional, Keating, M.M., additional, Sabloff, M., additional, Hilaire, E. St., additional, Kumar, R., additional, Delage, R., additional, Geddes, M., additional, Storring, J.M., additional, Shamy, A., additional, Elemary, M., additional, Lenis, M., additional, Francis, J., additional, Zhang, L., additional, and Buckstein, R., additional

Published
2017
Full Text
View/download PDF

19. P-116 Frailty is an independent prognostic marker for overall survival in MDS: Results of a Canadian MDS registry

Author

Buckstein, R., primary, Prica, A., additional, Chodirker, L., additional, Zhu, N., additional, Nevill, T., additional, Leitch, H., additional, Yee, K., additional, Leber, B.F., additional, Sabloff, M., additional, Kumar, R., additional, Geddes, M., additional, Lenis, M., additional, Li, C., additional, Mamedov, A., additional, Khalaf, D., additional, Zhang, L., additional, Rockwood, K., additional, Alibhai, S., additional, and Wells, R., additional

Published
2013
Full Text
View/download PDF

20. Changing frontline AML treatment patterns from 2013 to 2022.

Author

Brandwein JM, Ebeling K, Ding L, Liew E, Zhu N, Bolster L, Hamilton M, Hnatiuk M, and Wang P

Subjects
Humans, Aged, Treatment Outcome, Remission Induction, Antineoplastic Combined Chemotherapy Protocols adverse effects, Bridged Bicyclo Compounds, Heterocyclic, Retrospective Studies, Leukemia, Myeloid, Acute drug therapy
Abstract

The treatment patterns for patients with newly diagnosed acute myeloid leukemia (AML) were compared between 2013 and 16 and 2021-22 in a real-world setting. A significantly higher proportion of patients age 70 and over received non-intensive therapy (NIT) in 2021-22 as compared with 2013-16 (65 % vs 44 %, p = 0.014), with a corresponding reduction in the proportion receiving either intensive therapy or no antileukemic treatment. Treatment patterns among patients < age 70 were unchanged. The complete response rate in the NIT group was 69 % in 2021-22 vs. 24 % in 2013-16 (p < 0.001); the overall survival (OS) of NIT patients was 11.5 months in 2021-22 vs. 7.8 months in 2013-16. Older patients from rural areas were more likely to decline therapy than those from urban regions. The increase in the proportion of patients opting for NIT may be related to the availability of more effective treatment options. Although outcomes are improving, the OS with NIT remains suboptimal., Competing Interests: Declaration of Competing Interest J Brandwein – Advisory Boards with Honoraria: Abbvie, Amgen, Astellas, Avir, BMS/Celgene, Jazz, Pfizer, Paladin, Taiho., (Copyright © 2023. Published by Elsevier Ltd.)

Published
2023
Full Text
View/download PDF

21. Iron overload in myelodysplastic syndromes: Evidence based guidelines from the Canadian consortium on MDS.

Author

Leitch HA, Buckstein R, Zhu N, Nevill TJ, Yee KWL, Leber B, Keating MM, St Hilaire E, Kumar R, Delage R, Geddes M, Storring JM, Shamy A, Elemary M, and Wells RA

Subjects
Canada, Female, Humans, Male, Multicenter Studies as Topic, Practice Guidelines as Topic, Iron Overload diagnosis, Iron Overload metabolism, Iron Overload pathology, Iron Overload therapy, Myelodysplastic Syndromes diagnosis, Myelodysplastic Syndromes metabolism, Myelodysplastic Syndromes pathology, Myelodysplastic Syndromes therapy
Abstract

In 2008 the first evidence-based Canadian consensus guideline addressing the diagnosis, monitoring and management of transfusional iron overload in patients with myelodysplastic syndromes (MDS) was published. The Canadian Consortium on MDS, comprised of hematologists from across Canada with a clinical and academic interest in MDS, reconvened to update these guidelines. A literature search was updated in 2017; topics reviewed include mechanisms of iron overload induced cellular damage, evidence for clinical endpoints impacted by iron overload including organ dysfunction, infections, marrow failure, overall survival, acute myeloid leukemia progression, and endpoints around hematopoietic stem-cell transplant. Evidence for an impact of iron reduction on the same endpoints is discussed, guidelines are updated, and areas identified where evidence is suboptimal. The guidelines address common questions around the diagnosis, workup and management of iron overload in clinical practice, and take the approach of who, when, why and how to treat iron overload in MDS. Practical recommendations for treatment and monitoring are made. Evidence levels and grading of recommendations are provided for all clinical endpoints examined., (Copyright © 2018 Elsevier Ltd. All rights reserved.)

Published
2018
Full Text
View/download PDF

22. Incremental value of the bone marrow trephine biopsy in detecting residual leukemia following treatment for Acute Myeloid Leukemia.

Author

Saini L, Brandwein J, Turner R, Larratt L, Hamilton M, Peters A, Wu C, Zhu N, Taparia M, Patterson JM, Bolster L, Mant M, Ritchie B, Liew E, Mirza I, Quest G, Nahirniak S, Ghosh S, and Sandhu I

Subjects
Adolescent, Adult, Aged, Biopsy standards, Biopsy, Needle, Cohort Studies, Female, Humans, Immunohistochemistry, Leukemia, Myeloid, Acute drug therapy, Leukemia, Myeloid, Acute pathology, Male, Middle Aged, Neoplasm, Residual pathology, Retrospective Studies, Sensitivity and Specificity, Young Adult, Biopsy methods, Bone Marrow Examination standards, Leukemia, Myeloid, Acute diagnosis, Neoplasm, Residual diagnosis
Abstract

Most guidelines suggest that only the bone marrow aspirate (BMA) is necessary to assess residual disease following intensive chemotherapy for Acute Myeloid Leukemia (AML) with the bone marrow trephine biopsy (BMTB) recommended in cases of a poor quality BMA. We performed a retrospective study evaluating this in a cohort of patients receiving intensive chemotherapy for AML. Residual disease was assessed by morphological examination of the BMA and BMTB±immunohistochemistry. Of the 647 marrows 32.6% were interim marrows performed prior to peripheral count recovery, 41.7% were end of induction (EOI) marrows and the remaining were 'other marrows'. The BMA and BMTB findings were concordant in 92.8% of cases. The BMTB led to a change in diagnosis from 'no leukemia' to 'residual leukemia' in 5.2% of interim, 3.7% of EOI and 2.4% of 'other' marrows. The BMA alone had a sensitivity of 86.8% in detecting residual leukemia and of 82.3%, 82.5% and 94.2% for interim, EOI and 'other marrows', respectively. Despite the high concordance between the BMA and the BMTB the poor sensitivity of the BMA in detecting residual leukemia, particularly at EOI, may lead to an overestimation of the complete remission rates which may have therapeutic and clinical trial implications., (Copyright © 2016 Elsevier Ltd. All rights reserved.)

Published
2016
Full Text
View/download PDF

23. Isolation of siRNA target by biotinylated siRNA reveals that human CCDC12 promotes early erythroid differentiation.

Author

Fan C, Dong L, Zhu N, Xiong Y, Zhang J, Wang L, Shen Y, Zhang X, and Chen M

Subjects
Biotinylation, Cell Differentiation drug effects, Cell Proliferation, Erythroid Cells drug effects, Erythroid Cells metabolism, Erythropoiesis drug effects, Gene Expression Regulation, Developmental drug effects, Gene Expression Regulation, Developmental genetics, Gene Knockdown Techniques methods, Genes, Developmental drug effects, Genes, Developmental genetics, Genes, Developmental physiology, Humans, K562 Cells, Proteins genetics, Proteins metabolism, Proteins physiology, RNA, Small Interfering chemical synthesis, RNA, Small Interfering chemistry, RNA, Small Interfering isolation & purification, Time Factors, Transfection, Cell Differentiation genetics, Erythropoiesis genetics, Proteins isolation & purification, RNA, Small Interfering pharmacology
Abstract

Erythroid differentiation is a tightly regulated multi-step process that has not been fully elucidated. We previously reported that a siRNA screened from random siRNA library, siRNA clone-67, induced erythroid differentiation in human erythroleukemia K-562cell line. Here we identified that human CCDC12 (coiled-coil domain containing 12) is a target of siRNA clone-67, by target capture with biotinylated siRNA. Over-expression of CCDC12 in K-562cell up-regulated the expression of CD235, ε-globin and γ-globin, accelerated cell growth, and slightly down-regulated the expression of GATA-2. Knockdown of CCDC12 slowed down the cell growth. These data indicate that CCDC12 is a new participant that promotes early erythroid differentiation., (Copyright © 2011 Elsevier Ltd. All rights reserved.)

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results